Heba Nowyhed - Arcellx Chief Officer
| ACLX Stock | USD 83.42 3.56 4.09% |
Executive
Heba Nowyhed is Chief Officer of Arcellx
| Address | 800 Bridge Parkway, Redwood City, CA, United States, 94065 |
| Phone | 240 327 0603 |
| Web | https://www.arcellx.com |
Arcellx Management Efficiency
The company has return on total asset (ROA) of (0.0629) % which means that it has lost $0.0629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1079) %, meaning that it created substantial loss on money invested by shareholders. Arcellx's management efficiency ratios could be used to measure how well Arcellx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.09 in 2024. Return On Capital Employed is likely to drop to -0.13 in 2024. At this time, Arcellx's Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 752.2 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| Juan MD | Biomea Fusion | N/A | |
| John Soglia | Nuvalent | N/A | |
| Ravi Upasani | Biomea Fusion | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Benjamin Lane | Nuvalent | N/A | |
| Deborah JD | Nuvalent | 48 | |
| Thorsten Kirschberg | Biomea Fusion | 54 | |
| Matthew Moore | Ventyx Biosciences | 51 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Henry Pelish | Nuvalent | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Perrin BS | Nuvalent | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Sheila MD | Ventyx Biosciences | 54 | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0629 |
Arcellx Leadership Team
Elected by the shareholders, the Arcellx's board of directors comprises two types of representatives: Arcellx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcellx. The board's role is to monitor Arcellx's management team and ensure that shareholders' interests are well served. Arcellx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcellx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MBA, Chief Officer | ||
| Aileen Fernandes, Chief Officer | ||
| Kate Aiken, Chief Officer | ||
| Michelle Gilson, Chief Officer | ||
| Myesha Lacy, Chief Officer | ||
| Christopher MD, Chief Officer | ||
| MS JD, General Counsel | ||
| Heba Nowyhed, Chief Officer | ||
| Narinderjeet MS, Chief Officer | ||
| David Tice, Chief Officer | ||
| Neeraj Teotia, Chief Officer | ||
| Rami Elghandour, CEO Chairman |
Arcellx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcellx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0629 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (1.29) % | ||||
| Current Valuation | 4.19 B | ||||
| Shares Outstanding | 54.07 M | ||||
| Shares Owned By Insiders | 12.62 % | ||||
| Shares Owned By Institutions | 94.85 % | ||||
| Number Of Shares Shorted | 5.23 M | ||||
| Price To Book | 9.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Arcellx Stock Analysis
When running Arcellx's price analysis, check to measure Arcellx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcellx is operating at the current time. Most of Arcellx's value examination focuses on studying past and present price action to predict the probability of Arcellx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcellx's price. Additionally, you may evaluate how the addition of Arcellx to your portfolios can decrease your overall portfolio volatility.